Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trialAtsushi Nakajima, Michael Camilleri, Mitsunori Seki et al.|The Lancet. Gastroenterology & hepatology|2018Cited by 174
Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trialAtsushi Nakajima, Shinya Taniguchi, Mitsunori Seki|Journal of Gastroenterology|2017Cited by 62
Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE<sup>®</sup> tablet 5 mg)Naoki Ikeda, Mitsunori Seki, Shinya Taniguchi|Folia Pharmacologica Japonica|2019Cited by 1
744 - Medium-Term Efficacy and Long-Term Safety of Ileal Bile Acid Transporter Inhibitor, Elobixibat, in Chronic ConstipationAtsushi Nakajima, Michael Camilleri, Jan P. Mattsson et al.|Gastroenterology|2018Cited by 0